What is the current stock price of Royalty Pharma plc (RPRX)?

As of the latest market data, Royalty Pharma plc (RPRX) is trading at $47.90. The stock has seen a loss of -0.83% today.

Does Royalty Pharma plc (RPRX) pay a dividend?

Based on current data, Royalty Pharma plc does not have a confirmed active dividend policy.

What is the market cap of Royalty Pharma plc?

The current market capitalization of Royalty Pharma plc (RPRX) is approximately unavailable.

RPRX

Royalty Pharma plc·Healthcare

47.90

0.828%(−0.40)

Market Closed

49.05

2.401%(+1.15)

After Hours

Last Updated: — ET

52W L: $31.5852W H: $49.06

RPRX NEWS

defenseworld.net

5d ago

Aberdeen Group plc Acquires 98,191 Shares of Royalty Pharma PLC $RPRX

Aberdeen Group plc grew its stake in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 17.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 661,416 shares of the biopharmaceutical company's stock after purchasing an additional 98,191 shares during the quarter. Aberdeen Group

defenseworld.net

Apr 3

Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares of Stock

Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $48.33, for a total transaction of $1,681,449.03. Following the transaction, the chief financial officer owned 32,916 shares of the company's stock,

reuters.com

Mar 30

Royalty Pharma and J&J partner to develop autoimmune treatment

Royalty Pharma said on Monday it has signed a $500 million research and development agreement ‌with Johnson & Johnson to advance an experimental antibody treatment for autoimmune diseases.

globenewswire.com

Mar 30

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.

defenseworld.net

Mar 30

SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX

SG Americas Securities LLC lifted its stake in Royalty Pharma PLC (NASDAQ: RPRX) by 438.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 288,202 shares of the biopharmaceutical company's stock after purchasing an additional 234,629 shares during the

defenseworld.net

Mar 27

Terrance Coyne Sells 34,791 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of the company's stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $45.53, for a total transaction of $1,584,034.23. Following the completion of the transaction, the chief financial officer owned 43,886

Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2020-06-16

Beta

0.39

Websitewww.royaltypharma.com↗